NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
Clinical Trials
11 trialsNCT01240655 2020-12-19
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT01548924 2020-04-17
Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1 Terminated
NCT03503604 2018-04-20
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Phase 1 Unknown
NCT00891605 2017-11-21
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT01617928 2017-11-20
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT01297452 2017-03-31
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01930292 2016-03-24
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Debiopharm International SA
Phase 1 Terminated
NCT01245543 2015-11-02
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Withdrawn
NCT00556088 2010-12-30
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed